Blue Sparrow Partners
Blue Sparrow Partners is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Blue Sparrow Partners.
Blue Sparrow Partners is a company.
Key people at Blue Sparrow Partners.
Key people at Blue Sparrow Partners.
Blue Sparrow Partners is a California-based hedge fund manager and investment adviser established in 2017, focusing on discretionary investments primarily through pooled vehicles.[1][2][4] Led by founder Dror Bar-Ziv as controlling owner and managing partner, it manages approximately $111 million in total AUM, with $36 million from pooled investment vehicles and additional allocations from other sources, employing a small team of three (67% investors).[2][6] A related entity, Blue Sparrows MedTech Fund, targets early-stage medtech startups by providing capital solutions and industry expertise, indicating a venture-oriented arm within the broader hedge fund structure.[3] Its investment philosophy emphasizes targeted allocations in private funds and discretionary strategies, contributing to the startup ecosystem through medtech support, though public details on overall mission or key sectors beyond medtech remain limited.[1][3]
Blue Sparrow Partners was founded in 2017 by Dror Bar-Ziv, who serves as the controlling owner and managing partner.[1][4] Headquartered in Oakland, California (6114 La Salle Avenue), with a Delaware LP structure, the firm began as a hedge fund manager and has maintained a lean operation with three employees.[2][4] Its evolution includes growth in AUM to over $131 million in discretionary assets by recent filings, alongside the launch of Blue Sparrows MedTech Fund to focus on early-stage medtech investments.[3][6] Key pivotal moments include regulatory registrations (CRD #291440, SEC #801-117359) and steady expansion in pooled vehicles, reflecting a shift toward specialized startup funding amid hedge fund operations.[2]
Blue Sparrow Partners rides the wave of specialized medtech investing, where early-stage startups require both capital and domain expertise amid rising demand for healthcare innovations.[3] Timing aligns with post-2017 growth in venture-hedge hybrids, as market forces like biotech funding surges and regulatory easing favor nimble managers over large VCs. Its medtech focus influences the ecosystem by bridging hedge fund liquidity with startup needs, potentially accelerating innovations in medical devices and health tech, though its small scale limits broader disruption compared to mega-funds.[1][3]
Blue Sparrow Partners is poised for medtech expansion, leveraging its $111M AUM and founder-led model to capture more early-stage deals as AI-driven health tech trends accelerate.[2][3] Evolving regulations and interest rate shifts could boost discretionary strategies, while its lean team positions it to scale influence through high-conviction bets. Expect deeper ecosystem impact via successful medtech exits, solidifying its niche as a pragmatic player in startup funding.[6] This targeted approach, rooted in 2017 origins, underscores its edge in a crowded investment landscape.[1][4]
